Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by analysts at Stifel Nicolaus in a research report issued to clients and investors on Thursday, TipRanks reports.
Several other equities analysts have also issued reports on the company. Northland Securities set a $65.00 price target on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Friday. Cowen reiterated a “buy” rating and issued a $85.00 price objective on shares of Esperion Therapeutics in a report on Thursday. BidaskClub cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 1st. Goldman Sachs Group cut Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 price objective for the company. in a report on Wednesday, May 29th. Finally, Citigroup set a $73.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 28th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Esperion Therapeutics presently has a consensus rating of “Buy” and an average price target of $74.45.
ESPR opened at $49.59 on Thursday. Esperion Therapeutics has a 1 year low of $36.06 and a 1 year high of $60.99. The company has a market cap of $1.33 billion, a P/E ratio of -6.58 and a beta of 1.88.
In other news, CEO Timothy M. Mayleben bought 5,000 shares of the stock in a transaction dated Friday, March 29th. The stock was bought at an average price of $40.00 per share, for a total transaction of $200,000.00. Following the purchase, the chief executive officer now directly owns 61,163 shares in the company, valued at approximately $2,446,520. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nicole Vitullo sold 15,329 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $44.73, for a total value of $685,666.17. Following the completion of the transaction, the director now owns 8,319 shares of the company’s stock, valued at approximately $372,108.87. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BB Biotech AG lifted its stake in shares of Esperion Therapeutics by 3.4% in the 4th quarter. BB Biotech AG now owns 3,392,964 shares of the biopharmaceutical company’s stock valued at $156,076,000 after purchasing an additional 110,000 shares during the period. Pentwater Capital Management LP lifted its stake in shares of Esperion Therapeutics by 20.8% in the 1st quarter. Pentwater Capital Management LP now owns 2,476,500 shares of the biopharmaceutical company’s stock valued at $99,431,000 after purchasing an additional 426,200 shares during the period. FMR LLC lifted its stake in shares of Esperion Therapeutics by 43.8% in the 4th quarter. FMR LLC now owns 739,289 shares of the biopharmaceutical company’s stock valued at $34,007,000 after purchasing an additional 225,205 shares during the period. Wasatch Advisors Inc. lifted its stake in shares of Esperion Therapeutics by 13.4% in the 1st quarter. Wasatch Advisors Inc. now owns 637,789 shares of the biopharmaceutical company’s stock valued at $25,607,000 after purchasing an additional 75,165 shares during the period. Finally, Rhenman & Partners Asset Management AB lifted its stake in shares of Esperion Therapeutics by 35.5% in the 1st quarter. Rhenman & Partners Asset Management AB now owns 479,767 shares of the biopharmaceutical company’s stock valued at $19,263,000 after purchasing an additional 125,806 shares during the period.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Article: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.